Neue Entwicklungen in der Biopsiediagnostik früher und unklarer Lebertumoren

Zusammenfassung

Die bioptische Diagnostik früher und hochdifferenzierter Lebertumoren stellt besondere Anforderungen, denen die moderne Pathologie in vielfältiger Weise gerecht wird. So wurden differenzierte morphologische Algorithmen und neue immunhistologische Marker zur Differenzialdiagnose des hochdifferenzierten HCC und eine neue prognostisch relevante, molekularpathologische und histologische Klassifikation des Leberzelladenoms entwickelt. Durch diese neuen diagnostischen Werkzeuge gelingt es heute unter Einbeziehung der „Matrixdiagnostik” bei fast allen dieser schwierigen Fälle eine zuverlässige diagnostische Einstufung zu erreichen.

Abstract

Biopsy diagnosis of early and highly differentiated liver tumors is difficult and complex. Modern pathology has met this challenge by several different means; elaborate morphological algorithms and novel immunohistological markers support the differential diagnosis of highly differentiated HCC and a new, predictive molecular pathological and histological classification of liver cell adenoma was developed. By these new diagnostic tools together with the so-called ‘matrix diagnosis’ a reliable diagnostic classification is now feasible in the vast majority of these difficult cases.

Schlüsselwörter

Leberbiopsie - Diagnose - Klassikation - Marker - Lebertumoren

Key words

liver biopsy - diagnosis - classification - marker - liver tumor

Literatur

• 1 Giorgio A, Tarantino L, Stefano de G. et al . Complications after interventional sonography of focal liver lesions: a 22-year single-center experience.  J Ultrasound Med. 2003;  22 193-205
• 2 Stigliano R, Marelli L, Yu D. et al . Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC.  Cancer treatment reviews. 2007;  33 437-447
• 3 Navarro F, Taourel P, Michel J. et al . Diaphragmatic and subcutaneous seeding of hepatocellular carcinoma following fine-needle aspiration biopsy.  Liver. 1998;  18 251-254
• 4 Fattovich G, Stroffolini T, Zagni I. et al . Hepatocellular carcinoma in cirrhosis: incidence and risk factors.  Gastroenterology. 2004;  127 S35-S50
• 5 Bruix J, Sherman M. Management of hepatocellular carcinoma.  Hepatology. 2005;  42 1208-1236
• 6 Bruix J, Sherman M, Llovet J M. et al . Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.  J Hepatol. 2001;  35 421-430
• 7 Kudo M, Okanoue T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology.  Oncology. 2007;  72 (Suppl 1) 2-15
• 8 Ferrell L, Wright T, Lake J. et al . Incidence and diagnostic features of macroregenerative nodules vs. small hepatocellular carcinoma in cirrhotic livers.  Hepatology. 1992;  16 1372-1381
• 9 Theise N D, Schwartz M, Miller C. et al . Macroregenerative nodules and hepatocellular carcinoma in forty-four sequential adult liver explants with cirrhosis.  Hepatology. 1992;  16 949-955
• 10 Roncalli M, Roz E, Coggi G. et al . The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification.  Hepatology. 1999;  30 1174-1178
• 11 Quaglia A, Bhattacharjya S, Dhillon A P. Limitations of the histopathological diagnosis and prognostic assessment of hepatocellular carcinoma.  Histopathology. 2001;  38 167-174
• 12 Schrimacher P, Prange W, Dries V. et al . Highly differentiated hepatocellular tumors. Concepts, criteria, and differential diagnosis.  Pathologe. 2001;  22 407-416
• 13 Roncalli M. Hepatocellular nodules in cirrhosis: Focus on diagnostic criteria on liver biopsy. A Western experience.  Liver Transpl. 2004;  10 S9-S15
• 14 Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis.  Liver Int. 2005;  25 16-27
• 15 International Working Party . Terminology of nodular hepatocellular lesions. International Working Party.  Hepatology. 1995;  22 983-993
• 16 Wanless I R, Mawdsley C, Adams R. On the pathogenesis of focal nodular hyperplasia of the liver.  Hepatology. 1985;  5 1194-1200
• 17 Paradis V, Benzekri A, Dargere D. et al . Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma.  Gastroenterology. 2004;  126 1323-1329
• 18 Bioulac-Sage P, Rebouissou S, Sa Cunha A. et al . Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver.  Gastroenterology. 2005;  128 1211-1218
• 19 Yen Y H, Wang J H, Lu S N. et al . Contrast-enhanced ultrasonographic spoke-wheel sign in hepatic focal nodular hyperplasia.  European journal of radiology. 2006;  60 439-444
• 20 Hussain S M, Terkivatan T, Zondervan P E. et al . Focal nodular hyperplasia: findings at state-of-the-art MR imaging, US, CT, and pathologic analysis.  Radiographics. 2004;  24 3-17; discussion 18 – 19
• 21 Wanless I R, Albrecht S, Bilbao J. et al . Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain: a new syndrome.  Mod Pathol. 1989;  2 456-462
• 22 Ohmoto K, Honda T, Hirokawa M. et al . Spontaneous regression of focal nodular hyperplasia of the liver.  J Gastroenterol. 2002;  37 849-853
• 23 Ishak K G, Goodman Z D, Stocker J T. et al .Benign Hepatocellular Tumors. Tumors of the Liver and Intrahepatic Bile Ducts Washington; Armed Forces Institute of Pathology 2001: 9-48
• 24 Gyorffy E J, Bredfeldt J E, Black W C. Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use.  Ann Intern Med. 1989;  110 489-490
• 25 Foster J H, Berman M M. The malignant transformation of liver cell adenomas.  Arch Surg. 1994;  129 712-717
• 26 Ito M, Sasaki M, Wen C Y. et al . Liver cell adenoma with malignant transformation: a case report.  World J Gastroenterol. 2003;  9 2379-2381
• 27 Zucman-Rossi J, Jeannot E, Nhieu J T. et al . Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.  Hepatology. 2006;  43 515-524
• 28 Bioulac-Sage P, Rebouissou S, Thomas C. et al . Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry.  Hepatology. 2007;  46 740-748
• 29 Rebouissou S, Imbeaud S, Balabaud C. et al . HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation.  J Biol Chem. 2007;  282 14437-14446
• 30 Jeannot E, Poussin K, Chiche L. et al . Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma.  Cancer Res. 2007;  67 2611-2616
• 31 Torbenson M, Lee J H, Choti M. et al . Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway.  Mod Pathol. 2002;  15 189-196
• 32 Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma.  J Hepatol. 2008;  48 163-170
• 33 Sa Cunha A, Blanc J F, Lazaro E. et al . Inflammatory syndrome with liver adenomatosis: the beneficial effects of surgical management.  Gut. 2007;  56 307-309
• 34 Lepreux S, Laurent C, Le Bail B. et al . Multiple telangiectatic focal nodular hyperplasia: vascular abnormalities.  Virchows Arch. 2003;  442 226-230. Epub 2003
• 35 Marchio A, Terris B, Meddeb M. et al . Chromosomal abnormalities in liver cell dysplasia detected by comparative genomic hybridisation.  Mol Pathol. 2001;  54 270-274
• 36 Le Bail B, Bernard P H, Carles J. et al . Prevalence of liver cell dysplasia and association with HCC in a series of 100 cirrhotic liver explants.  J Hepatol. 1997;  27 835-842
• 37 Tsuda H, Hirohashi S, Shimosato Y. et al . Clonal origin of atypical adenomatous hyperplasia of the liver and clonal identity with hepatocellular carcinoma.  Gastroenterology. 1988;  95 1664-1666
• 38 Park Y N, Yang C P, Fernandez G J. et al . Neoangiogenesis and sinusoidal “capillarization” in dysplastic nodules of the liver.  Am J Surg Pathol. 1998;  22 656-662
• 39 Takayama T, Makuuchi M, Hirohashi S. et al . Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma.  Lancet. 1990;  336 1150-1153
• 40 Borzio M, Fargion S, Borzio F. et al . Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development.  J Hepatol. 2003;  39 208-214
• 41 Nagato Y, Kondo F, Kondo Y. et al . Histological and morphometrical indicators for a biopsy diagnosis of well-differentiated hepatocellular carcinoma.  Hepatology. 1991;  14 473-478
• 42 Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma.  Hum Pathol. 1991;  22 172-178
• 43 Di Tommaso L, Franchi G, Park Y N. et al . Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis.  Hepatology. 2007;  45 725-734
• 44 Garrido C, Gurbuxani S, Ravagnan L. et al . Heat shock proteins: endogenous modulators of apoptotic cell death.  Biochem Biophys Res Commun. 2001;  286 433-442
• 45 Chuma M, Sakamoto M, Yamazaki K. et al . Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma.  Hepatology. 2003;  37 198-207
• 46 Lai J P, Sandhu D S, Yu C. et al . Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma.  Hepatology. 2008;  47 1211-1222
• 47 Cheng W, Tseng C J, Lin T T. et al . Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway.  Carcinogenesis. 2008;  29 1319-1326
• 48 Moorman A F, Vermeulen J L, Charles R. et al . Localization of ammonia-metabolizing enzymes in human liver: ontogenesis of heterogeneity.  Hepatology. 1989;  9 367-372
• 49 Reitzer L J, Wice B M, Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells.  J Biol Chem. 1979;  254 2669-2676
• 50 Christa L, Simon M T, Flinois J P. et al . Overexpression of glutamine synthetase in human primary liver cancer.  Gastroenterology. 1994;  106 1312-1320
• 51 Schirmacher P, Prange W, Dries V. et al . Highly differentiated hepatocellular tumors. Concepts, criteria, and differential diagnosis.  Pathologe. 2001;  22 407-416
• 52 Rebouissou S, Amessou M, Couchy G. et al . Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.  Nature. 2008;  epub